Prostate Cancer Market Size, Share, Growth & Industry Analysis, By Drug Class (Hormonal ADT, AR-Directed Therapies, Cytotoxic agents, Bone metastases, Therapeutic Vaccines, PARP inhibitors and Others), By End-User (Hospital Pharmacies, Drug store & Retail pharmacies, and Online pharmacies), and Regional Analysis, 2024-2031

TABLE OF CONTENT

1 INTRODUCTION OF THE GLOBAL PROSTATE CANCER MARKET 
1.1 Market Definition
1.2 Market Segmentation
1.3 Research Timelines
1.4 Limitations
1.5 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY
3.1 Data Collection
3.1.1 Secondary Sources
3.1.2 Primary Sources
3.1.3 Research Flow
3.2 Subject Matter Expert Advice
3.3 Quality Check
3.4 Final Review
3.5 Bottom-Up Approach
3.6 Top-down Approach

4 GLOBAL PROSTATE CANCER MARKET OUTLOOK
4.1 Market Evolution
4.2 Overview
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.3.4 Challenges
4.4 Pricing Analysis
4.5 Porter’s Five Forces Analysis
4.6 Value Chain Analysis
4.7 Macroeconomic Analysis

5 IMPACT OF RUSSIA-UKRAINE WAR

6 GLOBAL PROSTATE CANCER MARKET, BY DRUG CLASS
6.1 Overview
6.2 Hormonal ADT
6.3 AR-Directed Therapies
6.4 Cytotoxic agents
6.5 Bone metastases
6.6 therapeutic vaccines
6.7 PARP inhibitors
6.8 Kinase inhibitors
6.9 PSMA-targeted radioligands

7 GLOBAL PROSTATE CANCER MARKET, BY END-USER
7.1 Overview
7.2 Hospital Pharmacies
7.3 Drug store & Retail pharmacies
7.4 Online pharmacies

8 GLOBAL PROSTATE CANCER MARKET, BY GEOGRAPHY
8.1 Overview

9 NORTH AMERICA 
9.1 U.S.
9.2 Canada
9.3 Mexico

10 EUROPE 
10.1 Germany
10.2 U.K.
10.3 France
10.4 Italy
10.5 Spain
10.6 Russia
10.7 Rest of Europe

11 ASIA-PACIFIC 
11.1 China
11.2 Japan
11.3 India
11.4 South Korea
11.5 Rest of Asia-Pacific

12 MIDDLE EAST & AFRICA 
12.1 GCC
12.2 South Africa
12.3 North Africa
12.4 Rest of Middle East & Africa

13 LATIN AMERICA 
13.1 Brazil
13.2 Argentina
13.3 Rest of South America

14 GLOBAL PROSTATE CANCER MARKET COMPETITIVE LANDSCAPE
14.1 Overview
14.2 Key Developments
14.3 Key Strategic Developments
14.4 Company Market Ranking
14.5 Regional Footprint
14.6 Industry Footprint

15 COMPANY PROFILES
15.1 Johnson & Johnson Services, Inc.
15.1.1 Key Facts
15.1.2 Financial Overview
15.1.3 Product Benchmarking
15.1.4 Recent Developments
15.1.5 Winning Imperatives
15.1.6 Current Focus & Strategies
15.1.7 Threat from competition
15.1.8 SWOT Analysis
15.2 Astellas Pharma Inc.
15.2.1 Key Facts
15.2.2 Financial Overview
15.2.3 Product Benchmarking
15.2.4 Recent Developments
15.2.5 Winning Imperatives
15.2.6 Current Focus & Strategies
15.2.7 Threat from competition
15.2.8 SWOT Analysis
15.3 Eli Lilly and Company
15.3.1 Key Facts
15.3.2 Financial Overview
15.3.3 Product Benchmarking
15.3.4 Recent Developments
15.3.5 Winning Imperatives
15.3.6 Current Focus & Strategies
15.3.7 Threat from competition
15.3.8 SWOT Analysis
15.4 Sanofi
15.4.1 Key Facts
15.4.2 Financial Overview
15.4.3 Product Benchmarking
15.4.4 Recent Developments
15.4.5 Winning Imperatives
15.4.6 Current Focus & Strategies
15.4.7 Threat from competition
15.4.8 SWOT Analysis
15.5 Ipsen Pharma
15.5.1 Key Facts
15.5.2 Financial Overview
15.5.3 Product Benchmarking
15.5.4 Recent Developments
15.5.5 Winning Imperatives
15.5.6 Current Focus & Strategies
15.5.7 Threat from competition
15.5.8 SWOT Analysis
15.6 Bayer AG
15.6.1 Key Facts
15.6.2 Financial Overview
15.6.3 Product Benchmarking
15.6.4 Recent Developments
15.6.5 Winning Imperatives
15.6.6 Current Focus & Strategies
15.6.7 Threat from competition
15.6.8 SWOT Analysis
15.7 AstraZeneca
15.7.1 Key Facts
15.7.2 Financial Overview
15.7.3 Product Benchmarking
15.7.4 Recent Developments
15.7.5 Winning Imperatives
15.7.6 Current Focus & Strategies
15.7.7 Threat from competition
15.7.8 SWOT Analysis
15.8 Valeant Pharmaceuticals International, Inc.
15.8.1 Key Facts
15.8.2 Financial Overview
15.8.3 Product Benchmarking
15.8.4 Recent Developments
15.8.5 Winning Imperatives
15.8.6 Current Focus & Strategies
15.8.7 Threat from competition
15.8.8 SWOT Analysis
15.9 Merck & Co., Inc.
15.9.1 Key Facts
15.9.2 Financial Overview
15.9.3 Product Benchmarking
15.9.4 Recent Developments
15.9.5 Winning Imperatives
15.9.6 Current Focus & Strategies
15.9.7 Threat from competition
15.9.8 SWOT Analysis
15.10 Pfizer Inc.
15.10.1 Key Facts
15.10.2 Financial Overview
15.10.3 Product Benchmarking
15.10.4 Recent Developments
15.10.5 Winning Imperatives
15.10.6 Current Focus & Strategies
15.10.7 Threat from competition
15.10.8 SWOT Analysis

LIST OF TABLES 

TABLE 1 Global Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 2 Global Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 3 Global Prostate Cancer Market Revenue, By Geography, 2021 – 2031 (USD Billion)
TABLE 4 North America Prostate Cancer Market Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 5 North America Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 6 North America Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 7 US Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 8 US Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 9 Canada Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 10 Canada Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 11 Mexico Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 12 Mexico Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 13 Europe Prostate Cancer Market Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 14 Europe Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 15 Europe Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 16 Germany Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 17 Germany Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 18 France Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 19 France Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 20 U.K. Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 21 U.K. Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 22 Spain Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 23 Spain Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 24 Italy Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 25 Italy Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 26 Russia Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 27 Russia Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 28 Rest of Europe Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 29 Rest of Europe Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 30 Asia-Pacific Prostate Cancer Market Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 31 Asia-Pacific Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 32 Asia-Pacific Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 33 China Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 34 China Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 35 Japan Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 36 Japan Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 37 India Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 38 India Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 39 South Korea Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 40 South Korea Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 41 Rest of Asia-Pacific Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 42 Rest of Asia-Pacific Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 43 Middle East and Africa Prostate Cancer Market Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 44 Middle East and Africa Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 45 Middle East and Africa Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 46 GCC Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 47 GCC Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 48 North Africa Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 49 North Africa Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 50 South Africa Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 51 South Africa Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 52 Rest of Middle East & Africa Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 53 Rest of Middle East & Africa Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 54 Latin America Prostate Cancer Market Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 55 Latin America Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 56 Latin America Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 57 Brazil Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 58 Brazil Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 59 Argentina Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 60 Argentina Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 61 Rest of Latin America Prostate Cancer Market Revenue, By Drug Class, 2021 – 2031 (USD Billion)
TABLE 62 Rest of Latin America Prostate Cancer Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 63 Company Market Ranking
TABLE 64 Regional Footprint
TABLE 65 Product Benchmarking
TABLE 66 Recent Developments
TABLE 67 Winning Imperatives

LIST OF FIGURES 

FIG. 1 Market Segmentation
FIG. 2 Research Timeline
FIG. 3 Global Prostate Cancer Market 2021-2031 (USD Billion)
FIG. 4 Global Prostate Cancer Market Geographical Analysis (CAGR %)
FIG. 5 Global Prostate Cancer Absolute Market Opportunity (USD Billion)
FIG. 6 Global Prostate Cancer Market Attractiveness (USD Billion)
FIG. 7 Global Prostate Cancer Market, By Drug Class, 2021-2031 (USD Billion)
FIG. 8 Global Prostate Cancer Market, By End-User, 2021-2031 (USD Billion)
FIG. 9 Research Methodology
FIG. 10 Research Process
FIG. 11 Bottom-Up Approach
FIG. 12 Top-Bottom Approach
FIG. 13 Market Dynamics Overview
FIG. 14 Porter's Five Forces Analysis
FIG. 15 Value Chain Analysis
FIG. 16 Macroeconomic Analysis
FIG. 17 Global Prostate Cancer Market Revenue Share, By Drug Class, 2023 and 2031 (%)
FIG. 18 Global Prostate Cancer Market Revenue Share, By End-User, 2023 and 2031 (%)
FIG. 19 Global Prostate Cancer Market Revenue Share, By Geographic Regions, 2023 and 2031 (%)
FIG. 20 Market Size and Projections, 2021 - 2031 (USD Billion)
FIG. 21 North America Prostate Cancer Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 22 Market Size and Projections, 2021 - 2031 (USD Billion)
FIG. 23 Europe Prostate Cancer Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 24 Market Size and Projections, 2021 - 2031 (USD Billion)
FIG. 25 Asia-Pacific Prostate Cancer Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 26 Market Size and Projections, 2021 - 2031 (USD Billion)
FIG. 27 Middle East & Africa Prostate Cancer Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 28 Market Size and Projections, 2021 - 2031 (USD Billion)
FIG. 29 Latin America Prostate Cancer Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 30 Key Strategic Development
FIG. 31 Key Facts
FIG. 32 Financial Overview
FIG. 33 SWOT Analysis